Specify a stock or a cryptocurrency in the search bar to get a summary
ProMIS Neurosciences Inc.
PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. Address: 1920 Yonge Street, Toronto, ON, Canada, M4S 3E2
Analytics
WallStreet Target Price
8.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PMN
Dividend Analytics PMN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PMN
Stock Valuation PMN
Financials PMN
Results | 2019 | Dynamics |